538.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$532.94
Aprire:
$534.84
Volume 24 ore:
973.80K
Relative Volume:
2.22
Capitalizzazione di mercato:
$26.84B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
19.89
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
+4.08%
1M Prestazione:
-4.41%
6M Prestazione:
+11.02%
1 anno Prestazione:
+79.96%
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp
|
538.84 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.45 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
10.03 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
72.66 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics Corp (UTHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
United Therapeutics CEO Rothblatt sells $5 million in shares - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
Form 4 United Therapeutics Corporation For: 27 July By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $5.05 million in stock - Investing.com
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: A Healthier Future with 25.5% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corp (UTHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
UTHR|United Therapeutics Corp|Price:528.470|Chg%:-1.060 - TradingKey
United Therapeutics Corp (NASDAQ: UTHR) CEO trades 9,500 shares in 10b5-1 plan - Stock Titan
United Therapeutics Corp. (UTHR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Form 4 United Therapeutics Corporation For: 24 July By Investing.com - Investing.com South Africa
United Therapeutics Corp. (UTHR) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
United Therapeutics Director Christopher Patusky Awarded Stock Options and Common Shares in Annual Equity Grant - Kalkine Media
United Therapeutics Director Christopher Causey Awarded Stock Options and Common Shares in Annual Equity Compensation - Kalkine Media
United Therapeutics Director Louis Sullivan Updates Stock Holdings and Receives Annual Stock Option Grant - Kalkine Media
United Therapeutics Corp. (UTHR) Earnings Dates, Call Summary & Reports - TipRanks
Form 4 United Therapeutics Corporation For: 23 July By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 23 July - Investing.com India
United Therapeutics CEO Rothblatt sells $5 million in shares By Investing.com - Investing.com Canada
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
United Therapeutics (UTHR) grants director Victor Dzau RSUs and stock options - Stock Titan
United Therapeutics (UTHR) director Victor Dzau submits initial Form 3 - Stock Titan
United Therapeutics (UTHR) awards RSUs and stock options to director - Stock Titan
United Therapeutics Corp (UTHR) awards RSUs and options to director - Stock Titan
United Therapeutics (UTHR) awards director 760 restricted stock units - Stock Titan
United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian - Stock Titan
United Therapeutics (UTHR) director gets RSU and stock option grants - Stock Titan
United Therapeutics (UTHR) awards RSUs and stock options to director Nilda Mesa - Stock Titan
United Therapeutics (UTHR) grants director 2,380 stock options at $527.07 - Stock Titan
United Therapeutics (UTHR) awards 2,380 stock options to director Causey - Stock Titan
United Therapeutics (UTHR) awards 2,380 stock options to board director - Stock Titan
United Therapeutics (UTHR) awards 760 RSUs in annual director grant - Stock Titan
United Therapeutics (NASDAQ: UTHR) grants stock units and options to director Kurzweil - Stock Titan
United Therapeutics Corp (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
United Therapeutics Boosts Board to 13 Members with Appointment of Esteemed Medical Expert Victor Dzau, M.D. - Kalkine Media
United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board - Stock Titan
After 12 years as NAM president, Victor Dzau joins United Therapeutics board - Stock Titan
United Therapeutics Corp. (UTH) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
United Therapeutics to report Q2 2026 results on August 5 - scanx.trade
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 - Yahoo Finance
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Form 4 United Therapeutics Corporation For: 21 July By Investing.com - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.05m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.05m in stock - Investing.com
United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale - Stock Titan
Boehringer Alleges United Therapeutics Poached Staff, Secrets - Law360
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $80,000 of UNITED THERAPEUTICS CORPORATION lobbying was just disclosed - Quiver Quantitative
United Therapeutics Corp (UTHR) - MSN
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Aug 06 '26 |
Sale |
517.05 |
8,300 |
4,291,512 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Aug 05 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Aug 05 '26 |
Sale |
518.74 |
9,500 |
4,927,985 |
324,443 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):